Keyphrases
Immune Checkpoint Inhibitors
56%
Non-small Cell Lung Cancer (NSCLC)
56%
Targeted Therapy
49%
Lung Cancer
41%
Personalized Medicine
37%
Precision Medicine
37%
Advanced Lung Adenocarcinoma
37%
Mutational Profile
37%
Molecular Tumor Board
37%
Groningen
28%
University Medical Centre
27%
Lung Cancer Treatment
22%
Small Cell Lung Cancer
22%
Non-responders
18%
CD8+ T Cell Infiltration
18%
Stereotactic Radiotherapy
18%
Lung Cancer Patients
18%
O6-methylguanine-DNA Methyltransferase
18%
Diagnostic Challenge
18%
Polymyalgia Rheumatica
18%
Promoter Methylation
18%
Navigational Bronchoscopy
18%
Circulating Tumor DNA (ctDNA)
18%
Early Treatment
18%
Mixed Cancer
18%
EGFR Exon 20
18%
Disease Treatment
18%
Neuroendocrine Tumor
18%
Expression Data
18%
Anaplastic Lymphoma Kinase
18%
Pulmonary Neuroendocrine Carcinoma
18%
Pulmonary Neuroendocrine Tumor
18%
Medicine Therapy
18%
Disease Pattern
18%
Molecular Diagnostics
18%
Chronic Myeloid Leukemia
18%
Short Communication
18%
Endosonography
18%
Mediastinoscopy
18%
Resectable Lung Cancer
18%
Recurrent Disease
18%
Carcinoma
15%
Cancer Cases
14%
Genetic Modification
14%
Median Progression-free Survival
12%
Methylguanine Methyltransferase
12%
Anaplastic Lymphoma Kinase Rearrangement
12%
CD8+ T Cells
11%
Solitary Pulmonary Nodule
11%
Apologizing
9%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Lung Cancer
63%
Targeted Therapy
57%
Neoplasm
51%
Anaplastic Lymphoma Kinase
37%
Personalized Medicine
37%
Bronchoscopy
37%
Biological Marker
37%
Immunotherapy
27%
Malignant Neoplasm
23%
Epidermal Growth Factor Receptor
21%
Small Cell Lung Cancer
20%
Exon
18%
Biopsy
18%
Neuroendocrine Tumor
18%
Lung Nodule
18%
Treatment of Small Cell Lung Cancer
18%
Diagnosis
18%
Resistance Mutation
18%
Neuroendocrine Carcinoma
18%
Promoter Region
18%
Osimertinib
18%
Durvalumab
18%
Methylation
18%
Stereotactic Radiotherapy
18%
Chronic Myelomonocytic Leukemia
18%
ALK Inhibitor
18%
Ticilimumab
18%
Primary Tumor
18%
Drug Megadose
18%
Molecular Diagnosis
18%
Methylated DNA Protein Cysteine Methyltransferase
18%
Endoscopic Ultrasound
18%
Mediastinoscopy
18%
Recurrent Disease
18%
Adverse Event
18%
Progression Free Survival
16%
Overall Survival
12%
Systemic Therapy
12%
Drug Therapy
12%
Treatment of Lung Cancer
12%
Radiation Therapy
10%
In Vitro
10%
Cancer Diagnostics
9%
Carcinoma
9%
Next Generation Sequencing
9%
Molecular Profiling
9%
Cancer
9%
Quality of Life
8%
Stereotactic Body Radiation Therapy
7%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
79%
Neoplasm
52%
Biological Marker
41%
Anaplastic Lymphoma Kinase
37%
Immune Checkpoint Inhibitor
37%
Immunotherapy
26%
Disease
26%
Progression Free Survival
24%
Epidermal Growth Factor Receptor
21%
Overall Survival
21%
Small Cell Lung Cancer
20%
Rheumatic Polymyalgia
18%
Circulating Tumor DNA
18%
Tolerability
18%
Durvalumab
18%
Osimertinib
18%
Neuroendocrine Carcinoma
18%
Neuroendocrine Tumor
18%
Anaplastic Lymphoma Kinase Inhibitor
18%
Tremelimumab
18%
Primary Tumor
18%
Lung Adenocarcinoma
18%
Methylated DNA Protein Cysteine Methyltransferase
18%
Adverse Event
15%
Carcinoma
9%
Systemic Treatment
7%
DNA Methyltransferase
7%
Chemotherapy
7%
Fluorodeoxyglucose F 18
5%
